Gastric and oesophageal cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 84
• PD-1 108
• PD-L1 49
• CLDN18 35
• TP53 1
• PI3K 1
• AKT 1
• STAT3 1
• mTOR 0
• CTNNB1 0
• VEGF 7
• YAP 0
• MAPK 0
• EGFR 10
• ERK 0
• FGFR 1
• JAK 0
• HIF-1 0
• MYC 0
• PTEN 3
• CTLA-4 8
• NRF2 0
• MET 5
• STING 0
• CXCR4 0
• B7-H3 6
• JNK 0
• AMPK 0
• GPX4 0
• TROP2 6
• IL-6 0
• METTL3 0
• COX-2 0
• KRAS 2
• ARID1A 1
• BRCA1 2
• FAK 0
• LAG-3 0
• MDM2 0
• MMP-9 0
• PARP 0
• PPAR 0
• TIGIT 1
• BRCA2 1
• HSP90 0
• BCL-2 0
• FTO 0
• SHP2 0
• BRAF 0
• CD47 1
• CDK4/6 0
• HDAC 0
• HER3 3
• HMGB1 1
• MEK 0
• PDGFR 2
• TIM-3 0
• TNF 0
• ATM 0
• AXL 2

24 of 2,590 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancers

  Catena Biosciences, Inc.· El Cerrito, United States· US$1,072,102 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  The role of IL-9 in gastric metaplasia and carcinogenesis

  Saint Louis University· Saint Louis, United States· US$2,541,122 awarded in fiscal year 2026· until Aug 2030

• NIH NCI · R01

  Mechanisms Underlying Emergence and Progression of Gastric Intestinal Metaplasia

  Pennsylvania State Univ Hershey Med Ctr· Hershey, United States· US$633,232 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Advancing the Use of the Kettles Esophageal and Cardia Adenocarcinoma Prediction Tool

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$543,710 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Comparative Modeling of Gastric Cancer Prevention, Screening, and Surveillance in the US

  Columbia University Health Sciences· New York, United States· US$1,238,857 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  IMproving the outcome of Peritoneal and Pleural metastases using Aerosolized ChemoTherapy (IMPACT)

  Universiteit Gent· Gent, Belgium· EU contribution €10,031,371· until Jun 2032· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Spatial profiling of gastric cancer with peritoneal carcinomatosis to tackle cancer spreading and improve precision immuno-oncology (SPARC)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Apr 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Dissecting chromosomal instability in gastric cancer and its role in immunoediting using advanced functional and multiplexed single cell sequencing technologies (CINbyFUNseq)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Netherlands· EU contribution €2,000,000· until Mar 2030

• European Commission (Horizon Europe) · HORIZON-EIC

  Hybrid endoscope for esophageal in vivo histology and histochemistry (ESOHISTO)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €3,643,628· until Jan 2029· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  In vivo Immunofluorescence-Optical Coherence Tomography (Immuno-OCT)

  Stichting Vu· Amsterdam, Netherlands· EU contribution €2,500,000· until Dec 2029

  The disease is named only in the funder's project summary, not in the title.

10 of 270 running projects, newest first. Listed amounts together: US$152.3m + €38.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

  NCT05462873· Novartis Pharmaceuticals· Updated 13 Nov 2026

  “Business decision and not related to safety concerns”Registry text, quoted unchanged. Source

• Suspended

  Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

  NCT03604991· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “End of Initial Phase of Multi-phase protocol”Registry text, quoted unchanged. Source

• Terminated

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Updated 10 Nov 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

  NCT05911243· University of Washington· Updated 3 Nov 2026

  “Study closed per SRC Low Accrual Policy.”Registry text, quoted unchanged. Source

• Suspended

  Adaptive Radiation for Abdominopelvic Metastases

  NCT05880667· Fox Chase Cancer Center· Updated 2 Nov 2026

  “Pending interim analysis”Registry text, quoted unchanged. Source

• Suspended

  HEARTS Trial for Thoracic Cancers

  NCT07132918· University of Wisconsin, Madison· Updated 30 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Suspended

  A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

  NCT04111172· Thomas Jefferson University· Updated 28 Oct 2026

  “Protocol is with FDA review, waiting for funding to be released”Registry text, quoted unchanged. Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Suspended

  Non-endoscopic EC Screening Program in Northern Iran

  NCT02311712· Tehran University of Medical Sciences· Updated 16 Oct 2026

  “Waiting to receive capsule sponge device from the manufacturer.”Registry text, quoted unchanged. Source

• Terminated

  Proton Beam Therapy in the Treatment of Esophageal Cancer

  NCT03482791· Washington University School of Medicine· Updated 2 Oct 2026

  “The study is no longer relevant to have open to ensure insurance approval for this patient population”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

  NCT06469944· Merck Sharp & Dohme LLC· Source

• Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  NCT06780111· Merck Sharp & Dohme LLC· Source

• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

  NCT04535401· National Cancer Institute (NCI)· Source

• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

  NCT04460937· National Cancer Institute (NCI)· Source

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Source

• Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  NCT06203600· National Cancer Institute (NCI)· Source

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  NCT04907643· Cedars-Sinai Medical Center· Source

• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

  NCT04704661· National Cancer Institute (NCI)· Source

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 71
• Organoids 34
• Mendelian Randomization Analysis 42
• CRISPR-Cas Systems 9
• Gene Expression Profiling 198
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 8
• Exome Sequencing 14
• Proteomics 55
• Metabolomics 42
• Mass Spectrometry 5
• Flow Cytometry 33
• Immunohistochemistry 151
• Liquid Biopsy 18
• Circulating Tumor DNA 25
• Xenograft Model Antitumor Assays 289
• Positron-Emission Tomography 22
• Magnetic Resonance Imaging 24
• Machine Learning 134
• Deep Learning 65
• Cohort Studies 175
• Genome-Wide Association Study 48

See which targets of this disease your abstract mentions, and go to the people working on them.